Holen Sie sich die Stockscreener-App
1.02
2.00%
0.02
Handel nachbörslich:
1.01
-0.01
-0.98%
Schlusskurs vom Vortag:
$1.00
Offen:
$1.04
24-Stunden-Volumen:
3.28M
Relative Volume:
0.55
Marktkapitalisierung:
$345.89M
Einnahmen:
$4.47M
Nettoeinkommen (Verlust:
$-71.67M
KGV:
-4.4003
EPS:
-0.2318
Netto-Cashflow:
$-59.58M
1W Leistung:
+0.00%
1M Leistung:
-22.73%
6M Leistung:
-43.02%
1J Leistung:
-42.37%
1-Tages-Spanne:
$1.01
$1.04
1-Wochen-Bereich:
$1.00
$1.10
52-Wochen-Spanne:
$0.97
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.02 | 345.89M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
3rd Circ. Topples Materiality Rule For Securities Suits - Law360
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen, Inc. (OCGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ocugen Row Revived as Third Cir. Dumps Investor Materiality Rule - Bloomberg Law News
A gene therapy poster will report three-year vision benefits across mutations - Stock Titan
Enterprise value to EBIT forward of Ocugen Inc – HAN:2H51 - TradingView
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen Inc Earnings and Revenue – HAN:2H51 - TradingView
Ocugen Inc Revenue Breakdown – HAN:2H51 - TradingView
Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN) - The Globe and Mail
Ocugen to Participate in Upcoming October Investor and Industry Conferences - GlobeNewswire
H.C. Wainwright raises Ocugen stock price target on Bahamas approval By Investing.com - Investing.com Nigeria
What's Behind Ocugen's (NASDAQ:OCGN) Big Moment in Healthcare Stocks? - kalkinemedia.com
H.C. Wainwright raises Ocugen stock price target on Bahamas approval - Investing.com
Ocugen's Retina Data Impress, but a 250 Million Share Vote Still Holds the Reins - AD HOC NEWS
Ocugen's Island Approval Arrives as a 250 Million Share Decision Waits in the Wings - AD HOC NEWS
Ocugen's Bahamian Green Light Meets a Shareholder Reckoning - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen receives provisional approval for gene therapy in Bahamas By Investing.com - Investing.com Nigeria
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy - MyChesCo
Ocugen Receives OCU400 Priority Designation in Bahamas - grafa.com
Why Is OCGN Stock Rising Today? - stocktwits.com
Ocugen Gets Provisional Approval for OCU400 in Bahamas - marketscreener.com
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days - Yahoo Finance
Ocugen's 32% Lesion Slowdown Meets a Balance Sheet That Won't Wait - AD HOC NEWS
OCGN Looks 22.0% Overvalued on GF Value™ - GuruFocus
Ocugen receives provisional approval for gene therapy in Bahamas - Investing.com
Ocugen Announces Expanded Access Program for OCU400 in Retinitis Pigmentosa Following LARTA Provisional Approval - quiverquant.com
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa - Ocugen, Inc.
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen (OCGN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Ocugen stockholders approve adjournment of special meeting for share increase vote - Investing.com Nigeria
Why Is Ocugen (NASDAQ:OCGN) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
Form 8K Ocugen, Inc For: 23 September By Investing.com - Investing.com Australia
Form 8K Ocugen, Inc For: 23 September - Investing.com India
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $9.5 - Moomoo
OCGN: Proposal to increase authorized shares delayed due to insufficient votes; adjournment approved - TradingView
OCGN: Proposal to increase authorized shares stalled; adjourned meeting set for further voting - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances - TradingView
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ocugen Inc-Aktie (OCGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
57,264 |
64,136 |
1,088,035 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):